Sheila Gujrathi (Gossamer Bio)

Gos­samer shares take an­oth­er beat­ing as its lead drug fails 2 key clin­i­cal stud­ies, high­light­ing harsh re­views for DP2

Ever since a key DP2 drug at No­var­tis called fe­vip­iprant failed a piv­otal line­up of clin­i­cal stud­ies by the end of last year, a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.